Appeals court breathes new life into Teva's Medicare pricing lawsuit
A federal appeals court has partially revived Teva Pharmaceuticals' lawsuit against the Medicare drug price negotiation program. The DC Circuit ruled on Tuesday that Teva's claims can proceed, after a lower court had dismissed the case last fall. The decision comes as Teva faces upcoming price cuts for its drug Austedo under the program.
The DC Circuit’s ruling on Tuesday marks a procedural win for Teva, allowing its legal challenge to the Medicare drug price negotiation program to move forward after a lower court dismissed the case last autumn. The appeals court did not rule on the merits but found that Teva’s claims were viable enough to proceed. Teva’s drug Austedo, used for movement disorders, is slated for price cuts under the program, making the company one of several manufacturers contesting the initiative’s constitutionality and implementation. The decision adds another layer of uncertainty to the program’s rollout, though the case remains in early stages.
This ruling could affect how drugmakers and Medicare interact over negotiated prices, potentially delaying or reshaping cost-saving measures for seniors. If Teva’s claims succeed, other manufacturers may follow, undermining the program’s momentum. Conversely, a swift resolution might clarify legal boundaries, giving patients more predictable access to medications. The impact hinges on court outcomes, which could influence drug pricing dynamics and federal healthcare policy for years.